NASDAQ · ESPR
Healthcare · Drug Manufacturers - Specialty & Generic
$3.18
Up+$0.00 (+0.00%)
Updated Aug 14, 2026, 1:51 AM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ESPR does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ESPR.
ESPR research
Company profile and research snapshot.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 4, 2026 | Needham | Hold | — |
| May 1, 2026 | HC Wainwright & Co. | Neutral | — |
| Mar 13, 2026 | Citizens | Market Outperform | — |
| Mar 3, 2026 | Needham | Buy | — |
| Nov 25, 2025 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Jul 20, 2026
For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on July 16,
Benzinga · Jul 1, 2026
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
SeekingAlpha · Mar 6, 2026
SeekingAlpha · Mar 3, 2026
Esperion Therapeutics, Inc. (ESPR) M&A Call March 3, 2026 8:00 AM ESTCompany ParticipantsSheldon Koenig - President, CEO & DirectorJohn Harlow -...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ESPR.
